Redox proteome analysis of auranofin exposed ovarian cancer cells (A2780)

Giovanni Chiappetta (1, 2) , Tania Gamberi (3) , Fiorella Faienza (4) , Xhesika Limaj (2, 1) , Salvatore Rizza , Luigi Messori (3) , Giuseppe Filomeni (4, 5) , Alessandra Modesti (3) , Joelle Vinh (1, 2)

1 SMBP - Spectrométrie de Masse Biologique et Protéomique (USR3149 / FRE2032)
2 PdC - Laboratoire Plasticité du Cerveau Brain Plasticity (UMR 8249)
3 UniFI - Università degli Studi di Firenze = University of Florence = Université de Florence
4 Università degli Studi di Roma Tor Vergata [Roma, Italia] = University of Rome Tor Vergata [Rome, Italy] = Université de Rome Tor Vergata [Rome, Italie]
5 UCPH - University of Copenhagen = Københavns Universitet

The effects of Auranofin (AF) on protein expression and protein oxidation in A2780 cancer cells were investigated through a strategy based on simultaneous expression proteomics and redox proteomics determinations. Bioinformatics analysis of the proteomics data supports the view that the most critical cellular changes elicited by AF treatment consist of thioredoxin reductase inhibition, alteration of the cell redox state, impairment of the mitochondrial functions, metabolic changes associated with conversion to a glycolytic phenotype, induction of ER stress. The occurrence of the above cellular changes was extensively validated by performing direct biochemical assays. Our data are consistent with the concept that AF produces its effects through a multitarget mechanism that mainly affects the redox metabolism and the mitochondrial functions and results into severe ER stress. Results are discussed in the context of the current mechanistic knowledge existing on AF.

Mots clés: Redox proteomics; Cysteine; Auranofin; Gold drugs; Ovarian cancer

Domaines: Cancer; Pharmacologie; Génomique, Transcriptomique et Protéomique [q-bio.GN]; Bio-Informatique, Biologie Systémique [q-bio.QM]

Giovanni Chiappetta, Tania Gamberi, Fiorella Faienza, Xhesika Limaj, Salvatore Rizza, et al.. Redox proteome analysis of auranofin exposed ovarian cancer cells (A2780). Redox Biology, 2022, 52, pp.102294. ⟨10.1016/j.redox.2022.102294⟩. ⟨hal-03616465⟩